Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis

Marienke A. A. M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete, Anna E. M. Bastiaansen, Marco W. J. Schreurs, Rob P. W. Rouhl, Cees A. van Donselaar, Marian H. J. M. Majoie, Rinze F. Neuteboom, Peter A. E. Sillevis Smitt, Roland D. Thijs, Maarten J. Titulaer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E2185-E2196
Number of pages12
JournalNeurology
Volume92
Issue number19
DOIs
Publication statusPublished - 7 May 2019

Keywords

  • FACIOBRACHIAL DYSTONIC SEIZURES
  • RECEPTOR ENCEPHALITIS
  • ILAE COMMISSION
  • POSITION PAPER
  • FOLLOW-UP
  • IMMUNOTHERAPY
  • EPILEPSY
  • CLASSIFICATION
  • AUTOIMMUNE
  • DEFINITION

Cite this

de Bruijn, M. A. A. M., van Sonderen, A., van Coevorden-Hameete, M. H., Bastiaansen, A. E. M., Schreurs, M. W. J., Rouhl, R. P. W., van Donselaar, C. A., Majoie, M. H. J. M., Neuteboom, R. F., Smitt, P. A. E. S., Thijs, R. D., & Titulaer, M. J. (2019). Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology, 92(19), E2185-E2196. https://doi.org/10.1212/WNL.0000000000007475